Manish Sagar is an Infectious Disease physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany Street
Shapiro Bldg Suite 9 B & C
Boston, MA 021182526
Telephone
617-414-4290Provider last certified this registry record 18 Jul 2024.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Melinta Therapeutics, LLCProgram year20241 payment
- CepheidProgram year20231 payment
- Novocure GmbHProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
62.8%Statin27.4%Rosuvastatin Calcium60%Atorvastatin Calcium40%Part D<11 patientsThiazide diuretic10.5%Hydrochlorothiazide100%Part D<11 patients+ 4 more classes in this area
Anti-infectives
14.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor14.5%Juluca81%Tivicay19%Part D<11 patientsMetabolism & gastrointestinal
8.2%Proton pump inhibitor5.4%Omeprazole100%Part D<11 patientsBiguanide (metformin)2.8%Metformin Hcl Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
13 NIH research awards on record, funded 2005–2026 per NIH RePORTER. The latest:
- HIV-1 antibodies in the presence of tuberculosis and other coinfections
Boston Medical Center
FY2026$872,596R01AI197970 - Mycobacterium Tuberculosis impact on HIV reservoir Clearance (MyTHIC)
Boston Medical Center
FY2026$795,622R01AI198006 - Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission
Boston Medical Center
FY2025$1,407,828R01AI172843
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”